Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 September 2015Website:
http://www.synlogictx.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 04 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
SYBX Latest News
Synlogic, Inc. (SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago.
Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release from Synlogic, this decision comes after an internal review of the clinical trial's progress.
Synlogic (NASDAQ: SYBX ) stock is sliding lower on Thursday after the biopharmaceutical company announced a reverse split for its shares. According to a press release from Synlogic, the company enacted a reverse stock split after markets closed yesterday.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference being held in New York, NY, June 7-9, 2023.
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What type of business is Synlogic?
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
What sector is Synlogic in?
Synlogic is in the Healthcare sector
What industry is Synlogic in?
Synlogic is in the Biotechnology industry
What country is Synlogic from?
Synlogic is headquartered in United States
When did Synlogic go public?
Synlogic initial public offering (IPO) was on 30 September 2015
What is Synlogic website?
https://www.synlogictx.com
Is Synlogic in the S&P 500?
No, Synlogic is not included in the S&P 500 index
Is Synlogic in the NASDAQ 100?
No, Synlogic is not included in the NASDAQ 100 index
Is Synlogic in the Dow Jones?
No, Synlogic is not included in the Dow Jones index
When was Synlogic the previous earnings report?
No data
When does Synlogic earnings report?
The next expected earnings date for Synlogic is 08 November 2024